Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Daiichi's broad cardiovascular pipeline

Sep. 13, 1996

Roberts cleared to market cardiovascular orphan drug

Sep. 13, 1996

New TNF-alpha inhibitors reported by Celgene

Sep. 13, 1996

Vasopressin antagonists from American Cyanamid

Sep. 13, 1996

Mitsui Toatsu claims long-acting oral form of MS-551

Sep. 13, 1996

Pharmacia & Upjohn discloses class III antiarrhythmic agents

Sep. 13, 1996

Antiarrhythmic peptides claimed by BASF

Sep. 13, 1996

Nebivolol claimed for oxidative stress-related disorders

Sep. 13, 1996

Inhibitors of ceramide-mediated signal transduction

Sep. 13, 1996

Researchers isolate sodium pump inhibitor from human placenta

Sep. 13, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...